2013-04-11 09:31:42 - David Lewis, Vice President of Biology at Arrowhead Research, will present at GTC’s 4th RNAi Research & Therapeutics Conference on June 20-21, 2013 in San Francisco, CA.
David Lewis, Vice President of Biology at Arrowhead Research, will present on “DPC Technology for siRNA Delivery: Moving from Platform to Pipeline” at GTC’s 4th RNAi Research & Therapeutics Conference on June 20-21, 2013 in San Francisco, CA.
Arrowhead Research has developed a platform technology for systemic siRNA delivery called Dynamic Polyconjugate (DPC). A key feature of DPC technology is a reversibly-masked, membrane-active polymer whose activity is revealed only in the acidic environment within endosomes.
A simple co-injection of hepatocyte-targeted DPC polymer and a liver-tropic, cholesterol-conjugated siRNA (chol-siRNA) results in highly effective target gene knockdown in both rodents and non-human primates at low chol-siRNA doses. This is accomplished without complex formation or interaction of the DPC polymer and the chol-siRNA prior
to reaching the target cell.
Dr. Lewis will discuss Arrowhead’s current work to develop this DPC technology for the treatment of chronic hepatitis B virus (HBV) infection. He will share how a single I.V. co-injection of hepatocyte-targeted and fully biodegradable DPC (NAG-MLP) with chol-siRNAs targeting conserved human HBV sequences resulted in profound repression of viral RNA and multi-log knockdown of viral proteins and DNA with long duration of effect in mouse models of chronic HBV infection. Moreover, this therapeutic approach holds great promise for patients chronically infected with HBV.
David Lewis is the Vice President of Biology at Arrowhead Research Corporation and Site Head of Arrowhead’s research and development facility in Madison, WI, USA. Dr. Lewis was a pioneer in the use of RNAi in animals and was the first to show that siRNAs could be used to inhibit gene expression in multiple tissues of adult mammals. Dr. Lewis is also a co-inventor of Dynamic PolyConjugate (DPC) nanotechnology for targeted delivery of siRNA, which is currently in clinical development. Prior to his role at Arrowhead, Dr. Lewis was Site Head and Director of Research at Roche-Madison.
GTC’s 4th RNAi Research & Therapeutics Conference will provide a forum for leaders from both academia and industry to share their perspective and progress in RNA delivery and validation applications and network with fellow scientists and principle investigators to discuss the future of RNA-related discovery.
To view the agenda, click here.
To view the speaker list, click here.
The conference is part of the Nucleic Acid Summit 2013, which includes a workshop and co-located conference:
Bioinformatics & Data Management Strategies Workshop
3rd Next-Generation Sequencing Conference
For more information, please visit www.gtcbio.com/rnai